Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
97.17
Nov 20 • 3:59 PM ET Dollar change-0.73 Percentage change(-0.75%)
Aftermarket Close
97.26
Aftermarket • 7:57 PM ET Dollar change+0.09 Percentage change(0.09%)
Index
RUT
Market Cap
6.35B
Enterprise Value
6.41B
Income
-246.76M
Sales
0.00M
Book/sh
0.20
Cash/sh
1.36
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
124
IPO
Oct 04, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
497.03
P/C
71.66
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.70
Current Ratio
1.70
Debt/Eq
11.66
LT Debt/Eq
11.24
Option/Short
Yes / Yes
EPS (ttm)
-4.08
EPS next Y
-3.76
EPS next Q
-1.00
EPS this Y
6.46%
EPS next Y
7.01%
EPS next 5Y
54.51%
EPS past 3/5Y
12.22% -8.23%
Sales past 3/5Y
- -
EPS Y/Y TTM
0.88%
Sales Y/Y TTM
-
EPS Q/Q
9.53%
Sales Q/Q
-
Insider Own
8.55%
Insider Trans
61.48%
Inst Own
93.73%
Inst Trans
-6.48%
ROA
-115.45%
ROE
-1360.91%
ROIC
-160.39%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.70%
SMA50
16.89%
SMA200
103.26%
Trades
Shs Outstand
64.31M
Shs Float
59.81M
52W High
112.79 -13.85%
52W Low
19.25 404.78%
Volatility
7.00% 6.64%
ATR (14)
6.64
RSI (14)
52.04
Beta
1.96
Rel Volume
0.40
Avg Volume
1.75M
Volume
693,222
Perf Week
-12.61%
Perf Month
13.28%
Perf Quarter
161.07%
Perf Half Y
168.20%
Perf YTD
247.53%
Perf Year
396.02%
Perf 3Y
3898.77%
Perf 5Y
-1.51%
Perf 10Y
-
Prev Close
97.90
Price
97.17
Change %
-0.75%
Consensus
Strong Buy
Avg. Price Target
$130.17
Implied Upside
+34.0%
Analysts9incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 24, 2026Resumed
GS logoGGoldman
Neutral$36-63.0%
May 11, 2026Upgrade
CChardan Capital Markets
Neutral → Buy$61-37.2%
Nov 11, 2025Upgrade
HH.C. Wainwright
Neutral → Buy$24-75.3%
Oct 24, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$24-75.3%
Sep 25, 2025Upgrade
BCS logoBBarclays
Underweight → Equal Weight$17-82.5%
Sep 22, 2025Initiated
JEF logoJJefferies
Buy$15-84.6%
Aug 14, 2025Upgrade
JPM logoJJP Morgan
Underweight → Neutral$15-84.6%
Dec 09, 2024Upgrade
JEF logoJJefferies
Hold → Buy$20-79.4%
Sep 05, 2024Initiated
HH.C. Wainwright
Neutral$3-96.9%
Dec 11, 2023Resumed
GS logoGGoldman
Sell$2-97.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorNov 04 '26Buy98.51160,65815,826,42020,343,130Nov 06 04:55 PM
BAKER BROS. ADVISORS LPDirectorNov 05 '26Buy98.5186,4328,514,41620,424,859Nov 06 04:55 PM
Yang TaiyinDirectorOct 23 '26Option Exercise2.3520,00047,00020,000Oct 26 05:00 PM
BORGESON JOHN A.Chief Financial OfficerOct 21 '26Option Exercise2.4930,00074,700241,930Oct 23 05:00 PM
BORGESON JOHN A.Chief Financial OfficerOct 21 '26Sale90.0130,0002,700,322211,930Oct 23 05:00 PM
JOHN BORGESONOfficerOct 21 '26Proposed Sale92.9730,0002,789,100Oct 21 04:21 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy88.77681,86660,529,35420,159,386Sep 30 04:31 PM
BAKER BROS. ADVISORS LPDirectorSep 29 '26Buy85.0533,7262,868,25520,191,214Sep 30 04:31 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy83.58418,32334,963,07719,515,907Sep 30 04:30 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy72.57807,84058,625,70819,121,134Sep 30 04:29 PM
PERLROTH VICTORChairman and CEOSep 25 '26Option Exercise4.201,280,5245,381,9433,676,062Sep 29 07:44 PM
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Option Exercise1.0430,00031,200241,930Jun 05 05:56 PM
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Sale34.1030,0001,023,009211,930Jun 05 05:56 PM
JOHN BORGESONOfficerJun 04 '26Proposed Sale33.8730,0001,016,100Jun 04 04:29 PM
BORGESON JOHN A.Chief Financial OfficerApr 15 '26Option Exercise1.0428,61429,759211,930Apr 16 05:00 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Option Exercise1.0430,00031,200213,316Apr 02 08:26 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Sale39.9230,0001,197,488183,316Apr 02 08:26 PM
JOHN BORGESONOfficerApr 02 '26Proposed Sale42.8130,0001,284,300Apr 02 04:23 PM
PERLROTH VICTORChairman and CEOMar 25 '26Option Exercise1.04300,000312,0002,395,538Mar 27 06:08 PM
BAKER BROS. ADVISORS LPDirectorDec 18 '25Buy23.002,608,69660,000,00818,358,772Dec 19 04:06 PM
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Co-FounderDr. Victor Perlroth M.D.
M.B.A.Mr. John A. Borgeson CPA
Chief Technology OfficerMr. Wayne To M.Phil.
M.P.H.Dr. Dolly S. Chang M.D.
Senior Vice President of DevelopmentDr. Hong Liang Ph.D.